RECRUITING Phase 1 ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Sponsor: Basilea Pharmaceutica • ClinicalTrials.gov ID: NCT07500181

Registry updated: 2026-09-14

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

BAL2420 (also known as BAL0302420) is being developed as an antibacterial agent for the treatment of severe infections caused by Gram-negative bacteria. In this study, the sponsor aims to investigate the safety, tolerability and pharmacokinetics (PK) of BAL2420 following administration of single ascending doses (Part A) and multiple ascending doses (Parts B and C) in healthy adult volunteers. In all parts of the study, in each cohort, a different dose of study drug is to be investigated against a matched placebo in a randomized and double-blind manner.

Interventions

BAL2420 or placebo (Drug)
Single ascending dose administration (SAD)
BAL2420 or placebo (Drug)
Multiple-ascending dose (MAD)
BAL2420 or placebo (Drug)
MAD

Eligibility criteria

Inclusion Criteria: * Body mass index: 18.0 to 30.0 kg/m2, inclusive, at screening * Total body weight: \> 50 kg at screening Exclusion Criteria: * Any uncontrolled or active major systemic disease, * Active infection * Acute illness within 5 days prior to the first study drug administration that, in the opinion of the Investigator, may impact safety assessments. * Clinically-significant physical examination, vital signs, laboratory safety tests, or ECG abnormalities * History of risk factors for QT prolongation or Torsades de Pointes * QTcF (Fridericia's corrected QT interval) \> 450 msec (males) and \> 470 msec (females) at screening. * Receipt of prescribed medication other than hormonal contraceptives within the 30 days prior to admission to the clinical site. * Receipt of over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) within 14 days prior to admission to the clinical site. * History of relevant drug and/or food allergies, particularly to antibiotics. * History of tobacco use or e-cigarette within the past 6 months prior to the first study drug administration. * History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 12 months prior to screening. * Average intake of more than 24 units of alcohol per week: one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits. * Positive screen for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis C virus antibodies, human immunodeficiency virus 1 and 2 antibodies, or syphilis at screening. Note: Hepatitis B vaccination is allowed.

Conditions

Healthy

Locations

ICON Early Clinical & Bioanalytical Solutions — Groningen, Netherlands

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment